Journal article
Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma
World journal of gastrointestinal oncology, Vol.9(1), pp.42-49
01/15/2017
DOI: 10.4251/wjgo.v9.i1.42
PMCID: PMC5241527
PMID: 28144399
Abstract
AIM
To investigate if pre-treatment platelet counts could provide prognostic information in patients with rectal adenocarcinoma that received neo-adjuvant treatment.
METHODS
Platelet number on diagnosis of stage II and III rectal cancer was evaluated in 51 patients receiving neo-adjuvant treatment and for whom there were complete follow-up data on progression and survival, as well as pathologic outcome at the time of surgery. Pathologic responses on the surgical specimen of patients with lower platelet counts (150-300 x 10(9)/L) were compared with these of patients with higher platelet counts (> 300 x 10(9)/L) by the. 2 test. Overall and progression free survival Kaplan-Meier curves of the two groups were constructed and compared with the Log-Rank test.
RESULTS
A significant difference was present between the two groups in regards to pathologic response with patients with lower platelet counts being more likely to exhibit a good or complete response to neo-adjuvant treatment than patients with higher platelet counts (P = 0.015). Among other factors evaluated, there was also a significant difference between the carcinoembryonic antigen (CEA) at presentation of patients that exhibited a good or complete response and those that had no response or a minimal to moderate response. Patients with a good or complete response were more likely to present with a CEA of less than 5 mu g/L (P = 0.00066). There was no significant difference in overall and progression free survival between the two platelet count groups (Log-Rank tests P = 0.42 and P = 0.35, respectively).
CONCLUSION
In this retrospective analysis of stage II and III rectal cancer patients, platelet counts at the time of diagnosis had prognostic value for neo-adjuvant treatment pathologic response. Pre-treatment CEA also held prognostic value in regards to treatment effect.
Details
- Title: Subtitle
- Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma
- Creators
- Morgan Steele - Sault Area Hosp, Clin Trial Unit, Sault Ste Marie P6B 0A8, ON, CanadaIoannis A. Voutsadakis - Sault Area Hosp, Dept Internal Med, Div Med Oncol, Sault Ste Marie P6B 0A8, ON, Canada
- Resource Type
- Journal article
- Publication Details
- World journal of gastrointestinal oncology, Vol.9(1), pp.42-49
- DOI
- 10.4251/wjgo.v9.i1.42
- PMID
- 28144399
- PMCID
- PMC5241527
- NLM abbreviation
- World J Gastrointest Oncol
- ISSN
- 1948-5204
- eISSN
- 1948-5204
- Publisher
- Baishideng Publishing Group Inc
- Number of pages
- 8
- Grant note
- Sault Ste. Marie Academic Medical Association, Ontario, Canada
- Language
- English
- Date published
- 01/15/2017
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984806508902771
Metrics
3 Record Views